linjc16/ctgov huggingface dataset:
Changes in Different Fat Compartments and Their Effect on Particular Manifestations of Metabolic Syndrome After Bariatric Procedures.

Study Overview
=================
Brief Summary
-----------------
The metabolic risks associated with obesity are closely correlated with central (abdominal), rather than a peripheral (gluteofemoral) fat pattern It has been shown that weight loss after bariatric surgery is followed by metabolic improvements. The amount of fat lost from each site may be independently regulated. Very scant information is found in the literature regarding the relative changes in different fat body compartments, and their effect on the improvement of the metabolic profile. In this study we define the absolute and relative changes in the different adipose tissue compartment after weight loss surgery

Detailed Description
-----------------
The metabolic risks associated with obesity are closely correlated with central (abdominal), rather than a peripheral (gluteofemoral) fat pattern. The amount of fat lost from each site may be independently regulated. Very scant information is found in the literature regarding the relative changes in different fat body compartments. Rapid and preferential reduction of visceral fat mass could occur in morbid obese with visceral obesity. It has been previously shown, and it was also partially confirmed in this study, that a reduction in visceral fat was associated with metabolic improvements that included improved glucose tolerance and reduced plasma insulin and lipid levels. This again suggests a threshold of proportional visceral fat loss, above which there is an improvement in insulin sensitivity and other component of metabolic syndrom. We will quantify the different fat compartments changes after bariatric surgery by means of CT scan.

Official Title
-----------------
Changes in Different Fat Compartments During Weight Loss and Their Effect on Particular Manifestations of Metabolic Syndrome After Bariatric Procedures.

Conditions
-----------------
Visceral Obesity, Morbid Obesity, Metabolic Syndrome

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Morbid obesity, Metabolic syndrome Exclusion Criteria: Previous abdominoplasty surgery, Previous major abdominal surgey

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
morbid obesity, metabolic syndrome, visceral fat, peripheral fat
Tele-dermatology Non-presential (TeleDermaSA)

Study Overview
=================
Brief Summary
-----------------
The purpose of the study is to evaluate the implementation of the Non-Face-to-Face Interconsultation of dermatology since it began to be used in August 2020 until August 2022 in the province of Salamanca (Spain)

Detailed Description
-----------------
Design: cross-sectional descriptive study. Subjects: The unit of analysis will be the NPIs performed in dermatology since its implementation in August 2020 until the present time in the health area of Salamanca. To analyze the face-to-face consultations to analyze the differences. A random sample of 500 PNCIs and 500 face-to-face consultations will be extracted. Measurements: To analyze the ICNP and face-to-face IC to dermatology registered in the computerized clinical history made in PC from Medora and registered in Jimena. To record the number of consultations, type of pathology referred, dermatology response time, discharges after assessment, face-to-face consultations required, delay time, treatment required, follow-up required or not, diagnostic coincidence, quality of the photographic image sent. A differentiated analysis will be made according to the use or not of the dermatoscope, type of center (urban, semi-urban and rural), gender of the patients and age groups.

Official Title
-----------------
Evaluation of the Implementation of Tele-dermatology, in Its Modality of Non-presential Inter-consultation, in the Province of Salamanca.

Conditions
-----------------
Teledermatology, Primary Care

Intervention / Treatment
-----------------
* Other: data collection protocol in clinical history


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: The unit of analysis will be the PNCIs performed in dermatology from Primary Care, registered in Medora software, with its corresponding photographic file, and its response in Jimena software of the dermatology service, from June 2021 to June 2022, one year. Exclusion Criteria: -

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Patients with non-face-to-face consultation<br>A sample of 500 patients who have undergone non-face-to-face consultation with dermatology | Other: data collection protocol in clinical history<br>* collection of data from the clinical history according to the established protocol<br>|
| Patients with face-to-face consultation<br>A sample of 500 patients who have undergone face-to-face consultation with dermatology | Other: data collection protocol in clinical history<br>* collection of data from the clinical history according to the established protocol<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Derivation rates per 10,000 h. | number of patients referred to the dermatology office | 1 year |
Effect of GABAB Agonist on Visceral Hyperalgesia in NCCP patientsChinese?

Study Overview
=================
Brief Summary
-----------------
The effect of baclofen (GABAB agonist), diltiazem (muscle relaxant) and placebo will be compared in a double-blinded randomized study for the treatment of NCCP. Cerebral cortical, brainstem and spinal evoked potentials before and after treatment will be evaluated. Results of this study will shed lights on pathogenesis and treatment of NCCP in Chinese.We hypothesize that Baclofen alleviates visceral hyperalgesia in NCCP patients by suppressing afferent sensory pathway.

Official Title
-----------------
Is Visceral Hyperalgesia the Culprit of Noncardiac Chest Pain in Chinese? Part 2: Effect of GABAB Agonist on Visceral Hyperalgesia in NCCP Patients

Conditions
-----------------
Non-Cardiac Chest Pain

Intervention / Treatment
-----------------
* Drug: Baclofen, Diltiazem


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Consecutive patients with monthly angina-like chest pain and negative coronary angiogram or scintigraphy Age between 18-70 Gastroesophageal reflux disease Psychiatric illness Cerebrovascular accident Active peptic ulceration Heart failure or cardiac bradyarrhythmia Epilepsy Pregnancy or lactating female Previous hypersensitivity to muscle relaxant

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Baclofen, Diltiazem|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Esophageal sensory and pain thresholds |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Symptom severity of chest pain at the end of treatment |  |  | 
| Evoked potential responses |  |  |
Augmenting Clozapine With Sertindole - SERCLOZ

Study Overview
=================
Brief Summary
-----------------
The purpose of the study is to determine whether addition of sertindole to clozapine treatment can improve psychosis or the metabolic side-effects of clozapine in patients with treatment-resistant schizophrenia.

Detailed Description
-----------------
Around 20 % of patients with schizophrenia are treatment-resistant. Clozapine is still the drug of choice for these patients but 2/3 will not respond adequately to clozapine. In the study clozapine treatment is augmented with sertindole. Patients are randomized to either clozapine or sertindole for 12 weeks and continue in a open-label study with sertindole for 12 weeks. The purpose of the open-label study is to determine whether clozapine dosage can be reduced due to the addition of sertindole.

Official Title
-----------------
Augmenting Clozapine With Sertindole - a Double Blinded Randomized Placebo Study

Conditions
-----------------
Schizophrenia

Intervention / Treatment
-----------------
* Drug: Serdolect
* Drug: placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: ICD10 diagnosis of schizophrenia (F20.0-3) Clozapine treatment minimum 6 months Total PANSS >65 No antipsychotic other than clozapine drug 1 month prior inclusion Exclusion Criteria: QTc >500 ms Violence to SPC of clozapine or Serdolect Major depression Significant substance misuse interfering with participating in the study Cardiovascular disease

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: A<br>Sertindole 16 mg | Drug: Serdolect<br>* 16 mg, 12 weeks<br>* Other names: sertindole;|
| Placebo Comparator: B<br>Placebo | Drug: placebo<br>* placebo<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| PANSS total score |  | 12 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| GAF |  | 12 weeks | 
| WHOQOL-BREF |  | 12 weeks | 
| CGI |  | 12 weeks | 
| DAI |  | 12 weeks | 
| Cognitive test |  | 12 weeks | 
| Fasting glucose |  | 12 weeks | 
| Lipids |  | 12 weeks | 
| Hb1Ac |  | 12 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Schizophrenia, Treatment-resistant, sertindole, clozapine
Excision Limits of Oral Cavity Tumor by Narrow Band Imaging

Study Overview
=================
Brief Summary
-----------------
This study evaluates the feasibility of the NBI technique in the detection of early cancer lesions.

Official Title
-----------------
Excision Limits of Oral Cavity Tumor by NARROW BAND IMAGING (NBI): Feasibility Trial

Conditions
-----------------
Cancer

Intervention / Treatment
-----------------
* Device: Location of the suspected lesions
* Procedure: Biopsy
* Procedure: Lesion excision/Surgery


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Primitive epidermoid cancer of the oral cavity, proved by histology, not treated previously, patient having a surgery No previous surgery for this cancer Age > 18 years Patient affiliated to health insurance Consent signed by the patient Exclusion Criteria: Metastatic or recurrent disease Health care impossibilities for geographic, social, psychic reasons

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Patient with oral cavity cancer<br>Patient treated by surgery for the oral cavity cancer | Device: Location of the suspected lesions<br>* The suspected lesions will be located before the excision, during the surgery. With traditional light NBI technique The images will be recorded and compared<br>Procedure: Biopsy<br>* In case of suspected lesions detected by the NBI technique, this area is biopsied<br>Procedure: Lesion excision/Surgery<br>* In case of positive biopsy, the suspected lesions is excised<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Reliability for detection of subclinical lesions | Concordance between the histological data and the lesions detected by the NBI technique | baseline | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Excision limits quality criteria | percentage of detection / percentage of false-negative | baseline | 
| Detection of suspect lesions | Identify the detection of suspect lesions, aloof from the primitive lesion (percentage of detection / percentage of true-positive) | baseline | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
oral cavity tumor, narrow band imaging, subclinical cancer lesion
Effects of Topical Cream for Pain Relief

Study Overview
=================
Brief Summary
-----------------
To perform a clinical proof-of-concept study on a novel topical formula for pain relief.

Detailed Description
-----------------
An open-label study where each participant will be involved in the study for 4 weeks. During the study participants will use the topical cream 1-2 times daily on the anatomical area(s) causing the most pain.

Official Title
-----------------
Document Magnitude and Timing for Pain Relief of Topical Cream

Conditions
-----------------
Chronic Pain

Intervention / Treatment
-----------------
* Other: Topical cream


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: BMI between 18.5 and 34.9 kg/m2 (inclusive) Chronic joint/muscle related pain for at least past 6 months Experiencing chronic pain in at least one specific anatomical area for more than 6 months. Exclusion Criteria: Cancer during past 12 months Chemotherapy during past 12 months Currently taking prescription pain medications Getting regular joint injections (such as cortisone shots); Immunization during last month Participation in another clinical trial study during this trial, involving an investigational product or lifestyle change Regularly experiencing headaches, including migraines Serious active illness within past 6 months Significant active uncontrolled illness (such as lymphoma, liver disease, kidney failure, heart failure). Skin allergies related to ingredients in test product.

Ages Eligible for Study
-----------------
Minimum Age: 21 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Intervention Model: Single Group Assignment
Interventional Model Description: An open-label study design where all study participants will receive the active test product and no placebo is used.
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Topical cream, 1 - 2 times daily<br>Application of a pea-sized amount of cream applied to skin over the area with chronic pain | Other: Topical cream<br>* Topical cream applied to painful joint or muscle<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in degree of pain | Pain questionnaire - yes/no, score 0-24 hours | 4 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Activity level | Activities of daily living questionnaire | 4 weeks |
Coaching in Childhood Asthma

Study Overview
=================
Brief Summary
-----------------
Asthma among low-income, minority children remains a prime example of health disparities that are resistant to change. Demonstrations of reductions in disproportionate hospitalizations in controlled trials are limited. We performed a controlled clinical trial of an Asthma Coach to reduce hospitalizations among low-income, African American children.

Official Title
-----------------
Phase 4 Study of Case Management and Environmental Control in Asthma

Conditions
-----------------
Asthma

Intervention / Treatment
-----------------
* Behavioral: Coaching, providing social support


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Mothers of children with asthma 2-8 years of age and hospitalized for an acute exacerbation, with Medicaid insurance, and living in St. Louis City Exclusion Criteria: Other respiratory disease present
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Active coaching<br>Telephone and in person coaching | Behavioral: Coaching, providing social support<br>* Active telephone and in person coaching<br>|
| Active Comparator: Usual care<br>Return to PCP for usual care | Behavioral: Coaching, providing social support<br>* Active telephone and in person coaching<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Rehospitalization |  | 2 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
childhood, asthma
The Role of Lactate in Viral and Bacterial Infection

Study Overview
=================
Brief Summary
-----------------
Acute upper respiratory tract infection(AURI) is common in children, and viral infection is the main cause. However, several children with viral infection are easy to suffer from secondary bacterial infection, and the mechanism is unclear.

Detailed Description
-----------------
Lactate is an important molecule in the spread and metastasis of tumor by suppressing the innate immune response. As is known, the immune system is not mature in children and it is reverse related to the age of children. An reasonable hypothesis is that the lactate is a independent risk factor in the children with viral infection progress to bacterial infection. Here, our aim is to test the hypothesis.

Official Title
-----------------
The Role of Lactate From Viral to Bacterial Infection

Conditions
-----------------
Viral Infection, Bacterial Infections, Lactate Blood Increase

Intervention / Treatment
-----------------
* Other: viral infection
* Other: viral and bacterial infection


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: child's age is from 0 to 18 years a child is at least diagnosed with viral infection Exclusion Criteria: one of the following conditions appeared: congenital heart disease or other abnormalities respiratory failure hereditary and/or metabolic disease

Ages Eligible for Study
-----------------
Minimum Age: 1 Minute
Maximum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| viral infection<br>a child is infected by virus only | Other: viral infection<br>* a child is infected by virus only<br>|
| viral and bacterial infection<br>a child is infected by virus and progress to bacterial infection | Other: viral and bacterial infection<br>* a child is infected by virus and progress to bacterial infection<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| level of lactate | level of lactate in both viral and viral and bacterial infection groups | three days after admission | 
| the level of lactate dehydrogenase(LDH) | level of LDH in both viral and viral and bacterial infection groups | three days after admission |
Awareness and Knowledge of the Surgical Safety Checklist Among Operational Staff in University Teaching Hospital, Kathmandu, Nepal: A Cross-sectional Questionnaire

Study Overview
=================
Brief Summary
-----------------
The introduction of the World Health Organization Surgical Safety Checklist (WHO SSC) is a priority to promote surgical safety. However, little is known regarding awareness and knowledge of the WHO SSC in developing countries. This study aimed to obtain region-specific information for the introduction of the checklist in a core medical institution in Nepal. The present research was a cross-sectional study using data from a survey conducted at the Tribhuvan University Teaching Hospital (TUTH) in Kathmandu, Nepal. A questionnaire was distributed to 150 healthcare professionals working in the operating theatre. Responses to the questionnaire were analysed descriptively and regression analyses identified factors associated with awareness of the checklist.

Official Title
-----------------
Awareness and Knowledge of the Surgical Safety Checklist Among Operational Staff in University Teaching Hospital, Kathmandu, Nepal: A Cross-sectional Questionnaire

Conditions
-----------------
Surgical Checklist

Intervention / Treatment
-----------------
* Other: questionnaire survey


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: have optimal experience Exclusion Criteria: less experience

Ages Eligible for Study
-----------------
Minimum Age: 24 Years
Maximum Age: 55 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: questionnaire survey|questionnaire survey|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Awareness of Surgical Safety Checklist | Whether medical staffs know about Surgical Safety Checklist, Participants can answer to the question for yes or no. | 24 weeks |